ADVERTISEMENT

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

< Previous Abstract  |  Next Abstract >

Save Article to My Profile      Download Citation      Request Permissions

Abstract |  References  |  Full Text: HTML, PDF (Size: 990K)  | Related Articles | Citation Tracking

Comparative Effects of Telmisartan in the Treatment of Hypertension
William B. White, MD
From the Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, CT
Correspondence to   William B. White, MD, Professor of Medicine, Chief, Section of Hypertension and Clinical Pharmacology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-3940
Copyright 2002 Le Jacq Communications, Inc.

(J Clin Hypertens. 2002;4:20–25)

ABSTRACT

Three separate randomized, double-blind, parallel-group, 12-week trials compared telmisartan with enalapril, lisinopril, and amlodipine for treating mild to moderate hypertension. Telmisartan 80 mg was associated with a significantly greater mean decrease in trough systolic and diastolic blood pressure than enalapril 20 mg (p<0.05). Mean decreases in trough systolic and diastolic blood pressure with telmisartan (40, 80, and 160 mg) and lisinopril (10, 20, and 40 mg) were similar. Telmisartan (40, 80, and 120 mg) provided greater decreases in mean hourly systolic and diastolic blood pressure throughout the 24-hour dosing interval, including the last 4 hours of the dosing period, than amlodipine (5 and 10 mg). Telmisartan was associated with a lower incidence of treatment-related cough than lisinopril and enalapril and less treatment-related angioedema than amlodipine. These data suggest that for treating mild to moderate hypertension, telmisartan has efficacy similar to lisinopril, greater efficacy than enalapril and amlodipine throughout the 24-hour dosing interval, and better tolerability than these angiotensin-converting enzyme inhibitors and amlodipine.


Manuscript received January 23, 2002; accepted February 27, 2002

DIGITAL OBJECT IDENTIFIER (DOI)
10.1111/j.1524-6175.2002.01585.x About DOI

Related Articles

  • Find other articles like this in Wiley InterScience
  • Find articles in Wiley InterScience written by any of the authors

Wiley InterScience is a member of CrossRef.

Cross Ref Member


Announcing

JCH now includes The Journal of the CardioMetabolic Syndrome.

Each month read current issues on the JCH site.

For past issues, click here.

Free Issue

Read archived issues of our FREE Cardiology NewsWire

Latest News and Information

Get 6 free issues of breaking news and research delivered to your inbox each year!

Register now

Announcing
ASH

Members log in here to access the full-text and archived issues of JCH

Not a member? Join now.

Sign Up Now
Sign Up Now
Sign Up Now

Sign Up Now

Be the first to know about new research in your field

Sign up for FREE e-alerts from Wiley-Blackwell journals!

Sign Up Now